Novoic specializes in AI-enabled software designed for the early detection of Alzheimer's disease and subtle cognitive impairments through speech analysis. Their technology enables earlier diagnosis anywhere within approximately 10 minutes, providing scalable and accessible testing based on how people speak.

They aim to scale access to early Alzheimer's detection to support effective treatment. Novoic's speech-based cognitive tests are low-burden, easy to use, and compatible with any smart device, making them suitable even for elderly and cognitively impaired individuals. Their proprietary AI models and algorithms are clinically validated and used by over 50 medical institutions to improve early-stage Alzheimer’s detection, differential diagnosis, and patient management.

Key features of their offerings include fully automated audio-verbal cognitive assessments, integration with clinical trials, HIPAA/GDPR compliance for data privacy, and strong security standards. Novoic supports real-world application, including underserved communities, and offers tools like the Storyteller for testing, a Dashboard for trial management, and a Speech API for customized integrations.